10-Q: LENSAR, Inc. Reports First Quarter 2024 Results with Revenue Growth

LENSAR, Inc. saw a 28% increase in revenue year-over-year in the first quarter of 2024, driven by higher system sales and procedure volumes.

Summary

• LENSAR, Inc. reported a 28% increase in total revenue for the three months ended March 31, 2024, reaching $10.6 million compared to $8.3 million in the same period of 2023.
• Product revenue increased by 31% to $7.4 million, primarily due to higher procedure volumes and system sales.
• Lease revenue grew by 20% to $1.9 million, and service revenue increased by 25% to $1.2 million.
• The company's net loss for the quarter was $2.2 million, an improvement from the $4.3 million loss in the first quarter of 2023.
• The installed base of LENSAR Laser Systems and ALLY Systems is approximately 310 as of March 31, 2024.
• The company is assessing a potential net impairment of up to $3.8 million related to certain intangible assets and contract liabilities.

Sentiment

Score: 7

Explanation: The document shows positive revenue growth and improved net loss, but also highlights risks and uncertainties, resulting in a moderately positive sentiment.

Positives

• The company experienced a significant increase in revenue, indicating strong demand for its products and services.
• The net loss decreased compared to the same period last year, suggesting improved financial performance.
• The company is successfully growing its installed base of laser systems.
• The company has a strong focus on innovation with the ALLY System.

Negatives

• The company continues to incur operating losses, although the loss has decreased compared to the previous year.
• The company is assessing a potential net impairment of up to $3.8 million related to certain intangible assets and contract liabilities.
• The company is subject to risks associated with global supply chain disruptions and inflationary pressures.

Risks

• The company's future success depends on the market acceptance of the ALLY System and its ability to obtain regulatory clearances in additional regions.
• The company faces competition from larger, more established companies with greater resources.
• The company's operations are subject to extensive government regulation and oversight.
• The company's ability to meet production goals for the ALLY System may be impacted by supply chain interruptions.
• The company is exposed to the credit risk of some of its customers.
• The company may be unable to accurately forecast customer demand and inventory levels.
• The company may be subject to product liability suits.
• The company may be subject to legal proceedings.
• The company may need to raise additional capital in the future, which may not be available on acceptable terms or at all.
• The company is subject to cybersecurity risks and data privacy and security laws.

Future Outlook

The company expects annual revenue and selling, general and administrative expenses to increase from current levels associated with the increase in ALLY System placements. The company's liquidity needs will be largely determined by the company's ability to successfully commercialize its products and the progression, additional regulatory clearances or certifications and launch of the ALLY System in additional jurisdictions in the future. The company may need to raise additional capital through equity or debt financings, borrowings under credit facilities or from other sources in the future.

Management Comments

• Management believes the Company's cash and cash equivalents on hand, together with cash generated from the future sale and lease of products, will provide sufficient funds for its operating, investing, and financing cash flows for a period of at least twelve months from the date of issuance of these financial statements.
• Management expects annual revenue and selling, general and administrative expenses to increase from current levels associated with the increase in ALLY System placements.

Industry Context

The medical device market is highly competitive and subject to rapid technological changes. LENSAR competes with large multinational companies and smaller emerging players. The company's success depends on its ability to innovate, obtain regulatory approvals, and gain market acceptance for its products.

Comparison to Industry Standards

• LENSAR's revenue growth of 28% is a positive sign, indicating strong demand for its products, but it is important to compare this to the growth rates of its competitors such as Alcon, Bausch + Lomb, and Johnson & Johnson to assess its relative performance.
• The company's net loss of $2.2 million is an improvement from the previous year, but it is still important to compare this to the profitability of its competitors to assess its financial health.
• The company's installed base of 310 laser systems is a key metric, but it is important to compare this to the installed base of its competitors to assess its market share.
• The company's reliance on a network of independent distributors is a common practice in the medical device industry, but it is important to assess the effectiveness of this strategy compared to competitors who may have direct sales forces in certain markets.
• The company's focus on the ALLY System is a key differentiator, but it is important to assess the market acceptance of this system compared to competing technologies.

Corporate Governance

Legal Proceedings

• Stockholders filed a Verified Amended Class Action Complaint against the Company and certain of its officers and members of the board of directors, alleging violations of Sections 14(a) and 20(a) of the Exchange Act, as well as Rule 14d-9 promulgated thereunder, and asserting claims challenging the adequacy of disclosures in the definitive proxy statement filed with the SEC on June 20, 2023.
• Defendants filed a motion to dismiss on February 26, 2024, and the parties will complete briefing on the motion to dismiss in May 2024.

Related Party Transactions

• In June 2023, the Company entered into an international distribution agreement in India with a company owned by an employee at that time. As of April 1, 2024, the owner is no longer an employee of the Company.

Stakeholder Impact

• Shareholders may be impacted by the potential net impairment of up to $3.8 million related to certain intangible assets and contract liabilities.
• Employees may be impacted by the company's growth and expansion efforts.
• Customers may benefit from the company's continued innovation and product development.
• Suppliers may be impacted by the company's supply chain management and purchasing decisions.
• Creditors may be impacted by the company's financial performance and ability to repay debt.

Next Steps

• The company will continue to focus on the commercialization of the ALLY System.
• The company will pursue further regulatory clearances for the ALLY System in additional jurisdictions.
• The company will continue to expand its sales and marketing efforts.
• The company will complete the impairment assessment during the three months ended June 30, 2024.

Key Dates

Keywords

ALLY System, cataract treatment, laser system, medical device, revenue growth, financial results, regulatory approvals, intellectual property, supply chain, stock options